Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver

[1]  Per Artursson,et al.  Rapid measurement of intracellular unbound drug concentrations. , 2013, Molecular pharmaceutics.

[2]  X. Chu,et al.  Species differences in drug transporters and implications for translating preclinical findings to humans , 2013, Expert opinion on drug metabolism & toxicology.

[3]  Kazuya Maeda,et al.  Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms. , 2013, Annual review of pharmacology and toxicology.

[4]  S. L. Goss,et al.  Effect of Ritonavir on 99mTechnetium–Mebrofenin Disposition in Humans: A Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIs , 2013, CPT: pharmacometrics & systems pharmacology.

[5]  Kazuya Maeda,et al.  Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. , 2013, Biopharmaceutics & drug disposition.

[6]  Malcolm Rowland,et al.  Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential , 2012, Pharmaceutical Research.

[7]  Aleksandra Galetin,et al.  Use of Mechanistic Modeling to Assess Interindividual Variability and Interspecies Differences in Active Uptake in Human and Rat Hepatocytes , 2012, Drug Metabolism and Disposition.

[8]  J. W. Higgins,et al.  Ablation of Both Organic Cation Transporter (Oct)1 and Oct2 Alters Metformin Pharmacokinetics but Has No Effect on Tissue Drug Exposure and Pharmacodynamics , 2012, Drug Metabolism and Disposition.

[9]  R. Braun,et al.  Uptake Rate of Cationic Mitochondrial Inhibitor MKT-077 Determines Cellular Oxygen Consumption Change in Carcinoma Cells , 2012, PloS one.

[10]  Kazuya Maeda,et al.  PET Imaging–Based Evaluation of Hepatobiliary Transport in Humans with (15R)-11C-TIC-Me , 2012, The Journal of Nuclear Medicine.

[11]  I. Hidalgo,et al.  Models to Predict Unbound Intracellular Drug Concentrations in the Presence of Transporters , 2012, Drug Metabolism and Disposition.

[12]  Hugh A. Barton,et al.  Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data , 2012, Drug Metabolism and Disposition.

[13]  Aleksandra Galetin,et al.  Simultaneous Assessment of Uptake and Metabolism in Rat Hepatocytes: A Comprehensive Mechanistic Model , 2012, Journal of Pharmacology and Experimental Therapeutics.

[14]  P. Sexton,et al.  Drug transporters in drug efficacy and toxicity. , 2012, Annual review of pharmacology and toxicology.

[15]  J. G. Kenna,et al.  In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans , 2012, Drug Metabolism and Disposition.

[16]  Jue Chen,et al.  Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans , 2012 .

[17]  G. Scheffer,et al.  Variations in ATP-Binding Cassette Transporter Regulation during the Progression of Human Nonalcoholic Fatty Liver Disease , 2011, Drug Metabolism and Disposition.

[18]  Kerby Shedden,et al.  The subcellular distribution of small molecules: a meta-analysis. , 2011, Molecular pharmaceutics.

[19]  Y Kumagai,et al.  Identification of the Rate‐Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study , 2011, Clinical pharmacology and therapeutics.

[20]  Aleksandra Galetin,et al.  Kinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs , 2011, Drug Metabolism and Disposition.

[21]  Yasuyoshi Watanabe,et al.  The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [¹¹C]telmisartan. , 2011, Molecular pharmaceutics.

[22]  M. Roberts,et al.  Toward a new age of cellular pharmacokinetics in drug discovery , 2011, Drug metabolism reviews.

[23]  A. Sparreboom,et al.  Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism , 2011, Clinical pharmacology and therapeutics.

[24]  N. Toyota,et al.  Effect of lapatinib on hepatic parenchymal enhancement on gadoxetate disodium (EOB)-enhanced MRI scans. , 2011, Journal of computer assisted tomography.

[25]  P. Neuvonen,et al.  Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.

[26]  Ulf Bredberg,et al.  Measurement of Unbound Drug Exposure in Brain: Modeling of pH Partitioning Explains Diverging Results between the Brain Slice and Brain Homogenate Methods , 2011, Drug Metabolism and Disposition.

[27]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[28]  Edward H. Kerns,et al.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery , 2010, Nature Reviews Drug Discovery.

[29]  Yu-Tse Wu,et al.  Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. , 2010, International journal of pharmaceutics.

[30]  E. van de Steeg,et al.  Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. , 2010, The Journal of clinical investigation.

[31]  Yuichi Sugiyama,et al.  Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters , 2010, Drug metabolism reviews.

[32]  Markus Grube,et al.  Hepatic Uptake of the Magnetic Resonance Imaging Contrast Agent Gd-EOB-DTPA: Role of Human Organic Anion Transporters , 2010, Drug Metabolism and Disposition.

[33]  N. Samani,et al.  Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction: The GEOSTAT-1 Study , 2010, Circulation. Cardiovascular genetics.

[34]  K. Sandy Pang,et al.  Response to Letter to the Editor on “Permeability, Transport, and Metabolism of Solutes in Caco-2 Cell Monolayers: A Theoretical Study” , 2010, Drug Metabolism and Disposition.

[35]  Kazuya Maeda,et al.  Investigation of the Rate-Determining Process in the Hepatic Elimination of HMG-CoA Reductase Inhibitors in Rats and Humans , 2010, Drug Metabolism and Disposition.

[36]  K. Brouwer,et al.  Hepatobiliary Disposition of Troglitazone and Metabolites in Rat and Human Sandwich-Cultured Hepatocytes: Use of Monte Carlo Simulations to Assess the Impact of Changes in Biliary Excretion on Troglitazone Sulfate Accumulation , 2010, Journal of Pharmacology and Experimental Therapeutics.

[37]  A. D. Rodrigues,et al.  Enzyme- and transporter-based drug-drug Interactions : progress and future challenges , 2010 .

[38]  Susan A Kadlubar,et al.  Enzymatic Basis of Phase I and Phase II Drug Metabolism , 2010 .

[39]  Y. Sugiyama,et al.  Model Analysis of the Concentration-Dependent Permeability of P-gp Substrates , 2010, Pharmaceutical Research.

[40]  Thierry Lavé,et al.  Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[41]  Lei Zhang,et al.  Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. , 2009, Molecular pharmaceutics.

[42]  Jianghong Fan,et al.  Interplay of transporters and enzymes in drug and metabolite processing. , 2009, Molecular pharmaceutics.

[43]  Thierry Lavé,et al.  Prediction of Pharmacokinetic Profile of Valsartan in Humans Based on in vitro Uptake‐Transport Data , 2009, Chemistry & biodiversity.

[44]  Thierry Lavé,et al.  Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. , 2009, Molecular pharmaceutics.

[45]  P. Neuvonen,et al.  ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2009, Clinical pharmacology and therapeutics.

[46]  C. Klaassen,et al.  Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[47]  C. Tse,et al.  Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[48]  Kazuya Maeda,et al.  Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.

[49]  K. Brouwer,et al.  Relationship between Drug/Metabolite Exposure and Impairment of Excretory Transport Function , 2009, Drug Metabolism and Disposition.

[50]  O. van Tellingen,et al.  Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the In vivo Elimination of Methotrexate and its Main Toxic Metabolite 7-hydroxymethotrexate , 2008, Clinical Cancer Research.

[51]  Shusheng Zhang,et al.  Determination of ascorbic acid in individual rat hepatocyte by capillary electrophoresis with electrochemical detection. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[52]  E. Arriaga,et al.  Recent advances in the analysis of biological particles by capillary electrophoresis , 2008, Electrophoresis.

[53]  K. Brouwer,et al.  Use of Tc-99m Mebrofenin as a Clinical Probe to Assess Altered Hepatobiliary Transport: Integration of In Vitro, Pharmacokinetic Modeling, and Simulation Studies , 2008, Pharmaceutical Research.

[54]  Direct visualization and quantification of the anticancer agent, cis‐diamminedichloro‐platinum(II), in human lung cancer cells using in‐air microparticle‐induced X‐ray emission analysis , 2008, Cancer science.

[55]  K. Pang,et al.  Permeability, Transport, and Metabolism of Solutes in Caco-2 Cell Monolayers: A Theoretical Study , 2008, Drug Metabolism and Disposition.

[56]  F. Schmidt.  Meta-Analysis , 2008 .

[57]  O. Cars,et al.  Tissue concentrations: do we ever learn? , 2007, The Journal of antimicrobial chemotherapy.

[58]  C. Gui,et al.  Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[59]  J Brian Houston,et al.  Saturable Uptake of Lipophilic Amine Drugs into Isolated Hepatocytes: Mechanisms and Consequences for Quantitative Clearance Prediction , 2007, Drug Metabolism and Disposition.

[60]  Shuzhong Zhang,et al.  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. , 2007, The Journal of clinical investigation.

[61]  Michael F. Santillo,et al.  Recent advances in capillary electrophoretic analysis of individual cells , 2006, Analytical and bioanalytical chemistry.

[62]  G. M. Pollack,et al.  Kinetic Considerations for the Quantitative Assessment of Efflux Activity and Inhibition: Implications for Understanding and Predicting the Effects of Efflux Inhibition , 2007, Pharmaceutical Research.

[63]  J. Houston,et al.  Uptake and Intracellular Binding of Lipophilic Amine Drugs by Isolated Rat Hepatocytes and Implications for Prediction of in Vivo Metabolic Clearance , 2006, Drug Metabolism and Disposition.

[64]  Kim L R Brouwer,et al.  Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[65]  Aiman Abrahim,et al.  Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[66]  J. Polli,et al.  The Steady-State Michaelis–Menten Analysis of P-Glycoprotein Mediated Transport Through a Confluent Cell Monolayer Cannot Predict the Correct Michaelis Constant Km , 2005, Pharmaceutical Research.

[67]  Robert J Riley,et al.  THE BINDING OF DRUGS TO HEPATOCYTES AND ITS RELATIONSHIP TO PHYSICOCHEMICAL PROPERTIES , 2005, Drug Metabolism and Disposition.

[68]  Malcolm Rowland,et al.  Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[69]  W. Stumpf.  Drug localization and targeting with receptor microscopic autoradiography. , 2005, Journal of pharmacological and toxicological methods.

[70]  Leslie Z. Benet,et al.  Ex Situ Inhibition of Hepatic Uptake and Efflux Significantly Changes Metabolism: Hepatic Enzyme-Transporter Interplay , 2004, Journal of Pharmacology and Experimental Therapeutics.

[71]  B. Lai,et al.  The direct mapping of the uptake of platinum anticancer agents in individual human ovarian adenocarcinoma cells using a hard X-ray microprobe. , 2003, Cancer research.

[72]  H. Kusuhara,et al.  Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. , 2003, Molecular pharmacology.

[73]  Ivan Nestorov,et al.  Whole Body Pharmacokinetic Models , 2003, Clinical pharmacokinetics.

[74]  K. Brouwer,et al.  Probenecid-associated alterations in valproate glucuronide hepatobiliary disposition: mechanistic assessment using mathematical modeling. , 2001, The Journal of pharmacology and experimental therapeutics.

[75]  M Rowland,et al.  Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. , 1998, The Journal of pharmacology and experimental therapeutics.

[76]  T. Steinberg,et al.  Organic anion transport in macrophage membrane vesicles. , 1990, The Journal of biological chemistry.

[77]  O. H. Viveros,et al.  Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[78]  F. Gottesfeld,et al.  99mTc-HIDA cholescintigraphy in Dubin-Johnson and Rotor syndromes. , 1982, Radiology.